- Conditions
- Acute Coronary Syndrome
- Interventions
- Dalcetrapib, Placebo
- Drug
- Lead sponsor
- DalCor Pharmaceuticals
- Industry
- Eligibility
- 45 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 186
- States / cities
- Alexander City, Alabama • Birmingham, Alabama • Fairhope, Alabama + 163 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 721–744
of 8,608
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Borderline Ovarian Serous Tumor, Low Grade Ovarian Serous Adenocarcinoma, Micropapillary Serous Carcinoma, Primary Peritoneal Carcinoma, Primary Peritoneal Low Grade Serous Adenocarcinoma, Recurrent Borderline Ovarian Surface Epithelial-Stromal Tumor
- Interventions
- Laboratory Biomarker Analysis, Pharmacological Study, Selumetinib, Selumetinib Sulfate
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 19 Years and older · Female only
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2020
- U.S. locations
- 49
- States / cities
- Los Angeles, California • Palo Alto, California • Hartford, Connecticut + 32 more
- Conditions
- Cachexia, Lymphoma, Lymphoproliferative Disorder, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- Juven, Non-Juven Supplement
- Dietary Supplement
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 17 Years to 120 Years
- Enrollment
- 472 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2009
- U.S. locations
- 230
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 181 more
- Conditions
- Melanoma, Metastases
- Interventions
- MDX-010 (anti-CTLA4) monoclonal antibody, MDX-1379 (gp100) Melanoma Peptide Vaccine
- Drug · Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,783 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 110
- States / cities
- Tucson, Arizona • Duarte, California • Encinitas, California + 78 more
- Conditions
- Neurologic Pain, Nociceptive Pain
- Interventions
- Not listed
- Lead sponsor
- Marwood LowCost Pharmacy
- Other
- Eligibility
- 18 Years to 85 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Ovarian Cancer
- Interventions
- Lurbinectedin (PM01183), Pegylated liposomal doxorubicin (PLD), Topotecan
- Drug
- Lead sponsor
- PharmaMar
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 442 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 28
- States / cities
- Peoria, Arizona • Greenbrae, California • La Jolla, California + 23 more
- Conditions
- Heart Failure, Congestive
- Interventions
- Case management using advanced nurse practitioners
- Behavioral
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 969 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2007
- U.S. locations
- 4
- States / cities
- Danville, Illinois • Indianapolis, Indiana • Ann Arbor, Michigan + 1 more
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Pracinostat, Azacitidine
- Drug
- Lead sponsor
- Helsinn Healthcare SA
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 17
- States / cities
- Duarte, California • Los Angeles, California • Pleasant Hill, California + 14 more
- Conditions
- Osteosarcoma
- Interventions
- Biospecimen Collection, Laboratory Biomarker Analysis, Questionnaire Administration
- Procedure · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 18 Years to 50 Years · Male only
- Enrollment
- 224 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 93
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 76 more
- Conditions
- Eczema
- Interventions
- Abrocitinib, Placebo
- Drug · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 6 Years to 11 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • North Little Rock, Arkansas • San Diego, California + 7 more
- Conditions
- Acute Coronary Syndrome
- Interventions
- Lixisenatide (AVE0010), Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 6,068 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 200
- States / cities
- Birmingham, Alabama • Foley, Alabama • Mobile, Alabama + 160 more
- Conditions
- Metastatic Osteosarcoma, Recurrent Osteosarcoma, Refractory Osteosarcoma, Stage IV Osteosarcoma AJCC v7, Stage IVA Osteosarcoma AJCC v7, Stage IVB Osteosarcoma AJCC v7
- Interventions
- Denosumab, Laboratory Biomarker Analysis, Pharmacological Study
- Biological · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 11 Years to 49 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 132
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 104 more
- Conditions
- Hepatitis C Virus
- Interventions
- Daclatasvir, Placebo, peg-interferon alfa-2a, ribavirin
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 558 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 33
- States / cities
- Montgomery, Alabama • La Jolla, California • Los Angeles, California + 26 more
- Conditions
- Multiple Myeloma
- Interventions
- LBH589
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 24
- States / cities
- Scottsdale, Arizona • Berkeley, California • Duarte, California + 19 more
- Conditions
- Atrial Fibrillation (AF)
- Interventions
- Pulmonary Vein Isolation, vMap® + Pulmonary Vein Isolation
- Procedure · Device
- Lead sponsor
- Vektor Medical
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 423 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 12
- States / cities
- Jonesboro, Arkansas • Clearwater, Florida • Jacksonville, Florida + 9 more
- Conditions
- Becker Muscular Dystrophy
- Interventions
- Sevasemten 10 mg, Sevasemten 5 mg, Sevasemten 12.5 mg, Placebo
- Drug
- Lead sponsor
- Edgewise Therapeutics, Inc.
- Industry
- Eligibility
- 12 Years to 50 Years · Male only
- Enrollment
- 244 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 26
- States / cities
- Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 23 more
- Conditions
- Schizophrenia
- Interventions
- Cognitive Remediation
- Drug
- Lead sponsor
- New York State Psychiatric Institute
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 16
- States / cities
- Granada Hills, California • Orange, California • New Haven, Connecticut + 11 more
- Conditions
- Thrombotic and Bleeding Events
- Interventions
- On-X Aortic Heart Valve replacement
- Device
- Lead sponsor
- On-X Life Technologies, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 510 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 15
- States / cities
- Tucson, Arizona • Hartford, Connecticut • Indianapolis, Indiana + 12 more
- Conditions
- Partial Epilepsy
- Interventions
- 800 mg QD Eslicarbazepine acetate, 1200 mg QD Eslicarbazepine acetate, Placebo
- Drug
- Lead sponsor
- Bial - Portela C S.A.
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 653 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 106
- States / cities
- Mobile, Alabama • Northport, Alabama • Phoenix, Arizona + 82 more
- Conditions
- Primary Immune Deficiency
- Interventions
- Human Normal Immunoglobulin for Subcutaneous Administration
- Biological
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 2 Years to 75 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Centennial, Colorado • North Palm Beach, Florida + 9 more
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Erlotinib, Docetaxel
- Drug
- Lead sponsor
- Gabi Chiorean, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 12
- States / cities
- Newark, Delaware • Chicago, Illinois • Bloomington, Indiana + 6 more
- Conditions
- HIV-1-infection
- Interventions
- Oral Lenacapavir, F/TAF, Subcutaneous Lenacapavir, TAF, BIC, B/F/TAF
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 49
- States / cities
- Phoenix, Arizona • Los Angeles, California • Palm Springs, California + 40 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- BOS161721, Placebo
- Drug
- Lead sponsor
- Boston Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 143 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 17
- States / cities
- Anniston, Alabama • El Cajon, California • Los Alamitos, California + 14 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Double-blind Abatacept, Double-blind Placebo, Open-label Abatacept
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,795 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2009
- U.S. locations
- 44
- States / cities
- Decatur, Alabama • Paradise, Arizona • Phoenix, Arizona + 41 more